A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-07-09
Adverse events
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-08-14 (study day 21); relationship: not assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-27 (study day 65); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 132); relationship: not assessed
Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 156); relationship: N
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-30 (study day 159); relationship: not assessed
Data queries
No data queries.